FDA
-
-
-
-
-
-
-
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
-
-
-
-
-
-
-
Roivant Sciences (ROIV) Reports Q4 Net Loss of $291.3M, Provides Business Update
-
-
-
-
-
331,396 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

